BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 14571488)

  • 21. Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.
    Russo JJ; Goodman SG; Cantor WJ; Fitchett D; Heffernan M; Borgundvaag B; Ducas J; Cohen EA; Džavik V; Mehta SR; Buller CE; Yan AT;
    Heart; 2014 Jun; 100(11):873-80. PubMed ID: 24449716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
    Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions.
    Pitts WR; Lange RA
    Thromb Haemost; 1999 Sep; 82 Suppl 1():136-8. PubMed ID: 10695505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
    Gumina RJ; Yang EH; Sandhu GS; Prasad A; Bresnahan JF; Lennon RJ; Rihal CS; Holmes DR; Singh M
    Mayo Clin Proc; 2008 Sep; 83(9):995-1001. PubMed ID: 18775199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dilemma of success: percutaneous coronary interventions in patients > or = 75 years of age-successful but associated with higher vascular complications and cardiac mortality.
    Assali AR; Moustapha A; Sdringola S; Salloum J; Awadalla H; Saikia S; Ghani M; Hale S; Schroth G; Rosales O; Anderson HV; Smalling RW
    Catheter Cardiovasc Interv; 2003 Jun; 59(2):195-9. PubMed ID: 12772238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.
    Chang SM; Yazbek N; Lakkis NM
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):193-7. PubMed ID: 15170709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa receptor blockade with coronary stent placement.
    Neumann FJ; Schömig A
    Semin Interv Cardiol; 1998 Jun; 3(2):81-90. PubMed ID: 10212499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of percutaneous coronary interventions in patients with non ST segment elevation acute coronary syndrome in catheterisation laboratory without on-site surgical back-up.
    Dudek D; Rakowski T; Legutko J; Mielecki W; Dziewierz A; Bartuś S; Rzeszutko Ł; Sadowski J; Zmudka K; Dubiel JS
    Kardiol Pol; 2003 May; 58(5):356-65; discussion: 365. PubMed ID: 14523483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease.
    van der Wieken LR
    Semin Interv Cardiol; 1999 Jun; 4(2):77-83. PubMed ID: 10473876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study.
    Gilchrist IC; Nickolaus MJ; Momplaisir T
    Catheter Cardiovasc Interv; 2002 May; 56(1):10-3. PubMed ID: 11979524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transradial coronary angioplasty and stent implantation in acute myocardial infarction: initial experience.
    Mathias DW; Bigler L
    J Invasive Cardiol; 2000 Nov; 12(11):547-9. PubMed ID: 11060565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
    J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing primary PCI beyond "door to intervention time"--are we there yet?
    Kaluski E; Maher J; Gerula C; Tsai S; Randhawa P; Saric M; Oghlakian G; Alfano D; Palmaro J; Haider B; Klapholz M
    Cardiovasc Revasc Med; 2010; 11(2):84-90. PubMed ID: 20347797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with primary angioplasty of acute myocardial infarction during cerebellar hemorrhage.
    Paolillo V; Gastaldo D; Ferrero B; Sega P; Oliveri G
    J Invasive Cardiol; 2002 Sep; 14(9):562-4. PubMed ID: 12205360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tirofiban and intracoronary stenting: evaluation of a new pharmacologic regimen.
    Amidon TM; Amidon JB; Benson JM; Coffler D
    J Invasive Cardiol; 1999 Dec; 11(12):718-21. PubMed ID: 10745471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
    Shimpi RA
    J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors.
    Kralev S; Krause B; Papavassiliu T; Lang S; Haghi D; Kälsch T; Dempfle CE; Borggrefe M; Süselbeck T
    Cardiol J; 2009; 16(3):234-40. PubMed ID: 19437397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Which, when, how?].
    Juárez Herrera U
    Arch Cardiol Mex; 2001; 71 Suppl 1():S85-90. PubMed ID: 11565353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.